

5175 '99 JUL 20 P12:25

912 Clark  
Ames, IA 50010  
July 13, 1999

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20857-0003

RE: Docket No. 98N-1265

To the FDA:

I send this letter as a consumer of health care services to register my concern and disapproval of the Memorandum of Understanding as published by the FDA on January 21, 1999. In its present form, the MOU, as well as the Compounding Section 503A of the Modernization Act, severely restricts the rights of the physicians and patients to obtain healthcare products from the provider of their choice. It also infringes on the rights of compounding pharmacists to serve the public's medical needs. My mother is an example of a patient who would be adversely affected by the MOU as currently drafted. She lives in Ames, Iowa, but Wisconsin is the closest source her doctor could find for natural progesterone.



Please ensure that healthcare consumers can continue to receive appropriate medications, including prescribed compounded medications regardless of where they live. Please amend the Memorandum of Understanding to maintain patient and physician access to compounding pharmacists.

Sincerely,

Piper Wall, DVM, PhD

98N-1265

C 4151



Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, MD 20857-0003

20857+0003

